Recent Updates
Recently added Catalysts
PRLD Positive Sentiment

Phase Ib Study of PRT543, an Oral Protein Arginine Methyltransferase 5 (PRMT5) Inhibitor, In Patients With Relapsed or Refractory, Splicing Factor-Mutant Myeloid Malignancies

Tuesday, December 10, 2024 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: The article discusses a Phase Ib study of PRT543, an oral PRMT5 inhibitor, aimed at patients with relapsed or refractory myeloid malignancies characterized by splicing factor mutations. The study involves a team of researchers and highlights the potential of PRT543 to address unmet medical needs in this patient population.
Price reaction · baseline $1.03 (2024-12-09 close) · hit pre-market · 2 other PRLD headline(s) in the window, move may be shared
day 0 close
-5.8%
day 1
-8.7%
day 3 · peak
-22.3%

Market Sentiment Analysis

POSITIVE FACTORS

  • PRT543 shows potential as a treatment for myeloid malignancies.
  • The study targets a specific mutation in splicing factors.
  • Inhibiting PRMT5 may provide new therapeutic options.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+217%
120-day peak, hindsight
Typical move
8.2%
average across 4 past catalysts
Cash runway
~29 mo
Minimal dilution risk
Lead asset
PRT1419
Phase 1 · Multiple Myeloma

Full Press Release Details

Jan Philipp Bewersdorf, Xiaoli Mi, Bin Lu, Andrew Kuykendall, David A. Sallman, Manish Patel, Don Stevens, Alexander Philipovskiy, Grerk Sutamtewagul, Lucia Masarova, Gina Keiffer, Amit Verma, Neha Bhagwat, Diane Heiser, Sunhee Ro, Wan-Jen Hong, Omar Abdel-Wahab, and Eytan M. Stein

Frequently Asked Questions

What is PRT543?

PRT543 is an oral inhibitor of protein arginine methyltransferase 5 (PRMT5).

What type of patients is the study focused on?

The study focuses on patients with relapsed or refractory myeloid malignancies.

What mutations does the study target?

The study targets splicing factor mutations in myeloid malignancies.

What is the phase of the study?

The study is a Phase Ib clinical trial.

ShareAdd on Google
Tags: PRLD Viatris Investor Conferences Healthcare PRT543 PRMT5 myeloid malignancies splicing factor mutations Phase Ib study
Last updated: Dec 10, 2024

Biotech snapshot

Cash runway
$152M liquidity · $5M/mo burn
~29 mo
Minimal dilution risk
Lead asset
PRT1419Phase 1
Multiple Myeloma →

Catalyst track record

+217%
best trade around PRLD's most recent catalyst

Peak hindsight return over a 120-day window, across 4 tracked FDA/PDUFA catalysts for PRLD.

See every catalyst's timing & PoA →